• Molecular NameRopinirole
  • SynonymRopinirol [INN-Spanish]; ropinirole; Ropinirole HCl; Ropinirole hydrochloride; Ropinirolum [INN-Latin]
  • Weight275.396
  • Drugbank_IDDB00268
  • ACS_NO91374-21-9
  • Show 3D model
  • LogP (experiment)2.84
  • LogP (predicted, AB/LogP v2.0)1.62
  • pka9.68, and 12.43
  • LogD (pH=7, predicted)0.87
  • Solubility (experiment)133 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.41
  • LogSw (predicted, AB/LogsW2.0)6.27
  • Sw (mg/ml) (predicted, ACD/Labs)5.66
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds8
  • TPSA53.16
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA non-ergoline dopamine agonist.
  • Absorption_value98.0
  • Absorption (description)Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption.
  • Caco_2N/A
  • Bioavailability55.0
  • Protein binding40.0
  • Volume of distribution (VD)7.5 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized primarily by CYP1A2 to inactive N-deisopropyl and hydroxy metabolites.
  • Half life6 h
  • ExcretionN/A
  • Urinary Excretion<10
  • Clerance11.2 ml/min/kg
  • ToxicitySymptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A